Skip to main content
. Author manuscript; available in PMC: 2012 Feb 1.
Published in final edited form as: Arterioscler Thromb Vasc Biol. 2010 Nov 11;31(2):306–312. doi: 10.1161/ATVBAHA.110.216986

Figure 3. Mice treated with rhIL-11 have in-vivo mobilization of CD34+/VEGFR2+ mononuclear cells.

Figure 3

Sv129 mice were implanted with osmotic pumps loaded with either PBS or rhIL-11 for 3 days. A. Mononuclear cells from the mouse blood were analyzed by flow cytometry and profiled according to their forward and side scatter. PBS treated mice showed fewer CD34+/VEGFR2+ mononuclear cells in the R2 quadrant (B) compared with rhIL-11 treated mice (C) under the same experimental condition. D. CD34+/VEGFR2+ mononuclear cell-mobilization peaked 3 days after rhIL-11 treatment, with rhIL-11-treated mice exhibiting a 20-fold increase in circulating CD34+/VEGFR2+ mononuclear cells compared with PBS control mice on day 3. Each bar represents the mean ± SEM of 6 mice. Unpaired student t-test, two tailed *= P< 0.05.